Literature DB >> 10458826

Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.

C M Abramovich1, R A Prayson.   

Abstract

BACKGROUND: Predicting the behavior of meningiomas based on histopathologic features alone has remained problematic.
DESIGN: This study retrospectively compared several histopathologic features and MIB-1 labeling indices (LIs) in recurrent meningiomas with those of nonrecurrent meningiomas. Six histopathologic features, including mitoses, necrosis, loss of architectural pattern, hypervascularity/hemosiderin deposition, prominent nucleoli, and nuclear pleomorphism, were compared between 32 recurrent and 27 nonrecurrent meningiomas using Fisher exact tests. MIB-1 LIs (% positive tumor cell nuclei) were compared using the Wilcoxon rank sum test.
RESULTS: The patients in the recurrent group included 26 women (mean age, 55 years), who developed 1 to 5 recurrences. Time intervals to the first recurrence ranged from 5 to 183 months (mean, 55 months). The nonrecurrent group included 21 women (mean age, 56 years), with follow-up ranging from 88 to 124 months (mean, 109 months). Of the histopathologic features evaluated, statistically significant differences between the recurrent and nonrecurrent groups were found only with respect to prominent nucleoli (P =.024) and nuclear pleomorphism (P <.001), both of which were more common in the recurrent group. In the recurrent group, 9 tumors were considered malignant (defined by brain invasion or metastasis) versus 2 of the nonrecurrent meningiomas. Nineteen percent of nonrecurrent tumors versus 41% of recurrent tumors had 2 or more of the 6 histopathologic features. MIB-1 LIs in the nonrecurrent group ranged from 0 to 8.3 (mean, 1.5) and were generally lower than those in the recurrent group (range, 0-32.5; mean, 5.4); no statistical difference was identified between these groups. No statistically significant difference with regard to histology or MIB-1 LIs was noted between the initially excised recurrent tumor and the most recently resected recurrence.
CONCLUSIONS: Of the histopathologic features examined, only prominent nucleoli and nuclear pleomorphism were found to be statistically more common in recurrent than nonrecurrent meningiomas. The mean MIB-1 LI was higher in the recurrent than in the nonrecurrent group, although there was no statistical difference between means and there was clear overlap with regard to MIB-1 LI ranges.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458826     DOI: 10.5858/1999-123-0793-HFAMLI

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  11 in total

1.  Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors.

Authors:  Francesco Maiuri; Marialaura Del Basso De Caro; Felice Esposito; Paolo Cappabianca; Viviana Strazzullo; Guido Pettinato; Enrico de Divitiis
Journal:  J Neurooncol       Date:  2007-01-17       Impact factor: 4.130

2.  Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters.

Authors:  Yoo-Jin Kim; Ralf Ketter; Wolfram Henn; Klaus D Zang; Wolf-Ingo Steudel; Wolfgang Feiden
Journal:  Virchows Arch       Date:  2006-10-03       Impact factor: 4.064

3.  Proliferation potential of spinal meningiomas.

Authors:  Florian Roser; Makoto Nakamura; Mattia Bellinzona; Rainer Ritz; Helmut Ostertag; Marcos S Tatagiba
Journal:  Eur Spine J       Date:  2005-05-31       Impact factor: 3.134

4.  The histopathological spectrum of human meningiomas.

Authors:  Thomas Backer-Grøndahl; Bjørnar H Moen; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

5.  The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas.

Authors:  L Maes; E Lippens; J P O Kalala; L de Ridder
Journal:  Cell Prolif       Date:  2005-02       Impact factor: 6.831

6.  ODC mRNA as a prognostic factor for predicting recurrence in meningiomas.

Authors:  A Klekner; A G Röhn; G Schillinger; R Schröder; N Klug; R I Ernestus
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

7.  Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas.

Authors:  Masaki Okada; Keisuke Miyake; Yoshihito Matsumoto; Nobuyuki Kawai; Katsuzo Kunishio; Seigo Nagao
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

8.  CD44 Expression in Meningioma and its Correlation with Proliferation Indices.

Authors:  Rasha Ramadan Mostafa; Rasha Ahmed Khairy
Journal:  J Clin Diagn Res       Date:  2017-08-01

9.  How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists.

Authors:  Zsuzsanna Varga; Joachim Diebold; Corina Dommann-Scherrer; Harald Frick; Daniela Kaup; Aurelia Noske; Ellen Obermann; Christian Ohlschlegel; Barbara Padberg; Christiane Rakozy; Sara Sancho Oliver; Sylviane Schobinger-Clement; Heide Schreiber-Facklam; Gad Singer; Coya Tapia; Urs Wagner; Mauro G Mastropasqua; Giuseppe Viale; Hans-Anton Lehr
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

10.  Degree of Resection and Ki-67 Labeling Index for Recurring Meningiomas.

Authors:  Richard Menger; David E Connor; Alvin Y Chan; Gary Jain; Anil Nanda
Journal:  Cureus       Date:  2017-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.